Fresenius Kabi
About Fresenius Kabi
Fresenius Kabi is a global health care company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. Within transfusion technologies, Fresenius Kabi offers products for collection and processing of blood components and for therapeutic treatment of patient blood by apheresis systems.
87 articles about Fresenius Kabi
-
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.
4/15/2024
Fresenius, via its operating company Fresenius Kabi, announced the immediate U.S. availability of Tyenne®, a biosimilar of Actemra®.
-
According to Fresenius Kabi, Tyenne is the first biosimilar to Genentech’s Acterma which has both IV and subcutaneous formulations approved by the FDA.
-
Fresenius Kabi Further Expands Oncology Portfolio with Launch of Cyclophosphamide for Injection, USP
2/28/2024
Fresenius Kabi announced today it has introduced Cyclophosphamide for Injection, USP, a generic substitute for Cytoxan, for use in treating several forms of cancer.
-
Fresenius Kabi Launches Posaconazole Injection for Prevention or Treatment of Fungal Infections
1/29/2024
Fresenius Kabi Launches Posaconazole Injection for Prevention or Treatment of Fungal Infections.
-
Fresenius Kabi and Mayo Clinic Enter into Multiyear Supply and Service Agreement for the Ivenix® Infusion System
12/14/2023
Fresenius Kabi announced it has signed a multiyear agreement under which the Mayo Clinic is expected to purchase 10,000 Ivenix® large-volume infusion pumps for its hospitals and clinics in Minnesota, Arizona and Florida.
-
Fresenius Kabi Introduces Smart Labels for Diprivan® with Embedded Fully Interoperable +RFID Technology
10/9/2023
Fresenius Kabi announced today it has introduced +RFID smart labels for Diprivan® (Propofol) Injectable Emulsion, USP, 200 mg per 20 mL in single-dose vials, sold in the United States.
-
Fresenius Kabi Named 2023 Supplier Partner of the Year by Vizient
10/3/2023
Fresenius Kabi has been named the 2023 Supplier Partner of the Year by Vizient, Inc., the nation’s largest provider-driven health care performance improvement company.
-
Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi
9/14/2023
Fresenius Kabi announced today it has signed an agreement with Virginia Oncology Associates (VOA) under which VOA will purchase the Ivenix Infusion System to deliver medications for its patients.
-
Fresenius Kabi and AABB Announce Start of 18th Annual Blood Collectors Week September 3-9, 2023
9/3/2023
Fresenius Kabi and AABB proudly announce the dates of the 18th annual Blood Collectors Week, which runs September 3-9, 2023.
-
Fresenius Kabi and Lupagen Enter into Strategic Development and Supply Agreement to Bring Cell and Gene Therapies to the Bedside
8/24/2023
Fresenius Kabi and Lupagen Inc. announced the companies have entered into a development and supply agreement for technologies designed to bring the delivery of cell and gene therapies to the bedside.
-
Fresenius Kabi Launches Plerixafor Injection
8/9/2023
Fresenius Kabi announced it has introduced Plerixafor Injection, a generic equivalent to Mozobil®, available immediately in the United States in a 24 mg per 1.2 mL single dose vial.
-
Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection
8/8/2023
Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection.
-
Prometheus Laboratories Announces Collaboration with Fresenius Kabi on Anser Testing
8/1/2023
Prometheus Laboratories Inc. today announced a collaboration with Fresenius Kabi to support the validation of and access to Anser therapeutic drug monitoring (TDM) services for eligible patients receiving the Fresenius Kabi biosimilar, IDACIO (adalimumab-aacf).
-
Fresenius Kabi Introduces New Presentation for Fentanyl Citrate Injection, USP in Simplist® Ready-to-Administer Prefilled Syringes
7/11/2023
Fresenius Kabi Introduces New Presentation for Fentanyl Citrate Injection, USP in Simplist ® Ready-to-Administer Prefilled Syringes.
-
Expanding Access to Women’s Health Fresenius Kabi Launches Generic Fertility Treatment
7/10/2023
Fresenius Kabi announced it has launched Ganirelix Acetate Injection, a generic fertility drug, as part of the company’s expansion in women’s health.
-
IDACIO® (adalimumab-aacf) Now Available in the United States
7/3/2023
Fresenius Kabi announced today the immediate availability in the U.S. of its citrate-free adalimumab biosimilar IDACIO® (adalimumab-aacf) for use in the treatment of chronic autoimmune diseases for all eligible indications of the reference product, Humira® (adalimumab).
-
Metrodora Institute, a Leader in Treating Complex Conditions, Chooses the Ivenix Infusion System from Fresenius Kabi
6/29/2023
Fresenius Kabi announced that its Ivenix® Infusion System has been selected by the Metrodora Institute to meet the Institute’s infusion medicine needs.
-
Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio
6/14/2023
Fresenius Kabi announced the availability in the United States of Vasopressin Injection, USP, a generic equivalent to Vasostrict®.
-
Supporting Patient Safety: Fresenius Kabi Expands Ready-to-Administer Portfolio with Diazepam Injection, USP in Simplist® Prefilled Syringe
5/31/2023
Fresenius Kabi announced the launch and immediate availability in the U.S. of Diazepam Injection, USP in 10 mg per 2 mL Simplist® ready-to-administer prefilled syringes.
-
Fresenius Kabi Awarded Technology Breakthrough Agreement with Premier, Inc. for the Ivenix Infusion System
5/23/2023
Fresenius Kabi announced it has been awarded a Breakthrough Technology group purchasing agreement with Premier, Inc. Effective May 1, 2023, the new agreement allows Premier members, at their discretion, to benefit from special pricing and terms pre-negotiated by Premier for the Ivenix Infusion System from Fresenius Kabi.